We also sought to investigate whether combined anti-CD47 therapy and the anti-HER2 ADC, T-DM1 would be more effective than monotherapy using two in-vivo xenograft models: (1) A BRCA1 mutated high grade serous ovarian cancer model (chemotherapy and PARP inhibitors resistant) that exhibits HER2 and MYC amplification, (2) A very aggressive chemotherapy naïve uterine serous carcinoma model that exhibits HER2 and CCNE1 amplification as well as TP53 and PIK3CA mutations. The gene discussed is ERBB2; the disease is endometrial serous adenocarcinoma.